Integration of Radiotherapy with New Systemic Treatments for Breast Cancer

There is a significant gap in the knowledge and practice of integrating novel systemic therapies with radiotherapy in breast cancer management, particularly due to limited clinical trial data on their combined use. This gap affects both curative and metastatic settings, where the rapid emergence of targeted therapies—such as CDK4/6 inhibitors, anti-HER2 agents, PARP inhibitors, and immune therapies—creates uncertainty around sequencing, synergy, and potential toxicities. Additionally, managing complex scenarios like central nervous system metastases requires addressing unique challenges such as the blood-brain barrier and subtype-specific biological behavior. This educational activity addresses these gaps by providing evidence-based guidance, best-practice recommendations, and tools for radiation oncologists to enhance treatment integration and patient outcomes.

Topics:

  1. Radiotherapy in the Metastatic Setting: Navigating Synergy, Sequencing, and Safety with Targeted Therapies
    Icro Meattini, MD
  2. Integrating Radiation and New Systemic Agents in Breast Cancer: Her2, Immunotherapy, and PARPi Agents
    Mylin A. Torres, MD, FASTRO
  3. Central Nervous System Metastases in Breast Cancer: Challenges and Innovations in Systemic Therapy and Radiation Integration
    Sasha Beyer, MD, PhD
  4. Q and A
    Naamit Kurshan Gerber, MD - Moderator
    Full Panel

This activity is available from November 19, 2025, through 11:59 p.m. Eastern time on November 18, 2027. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Understand the potential toxicity of concurrent systemic agents and adjuvant breast radiation after seeing current data.
  • Understand evidence regarding safety profile of new systemic therapies when used in combination or sequentially with ablative or palliative radiotherapy for metastatic breast cancer.
  • Know the specific concerns regarding combined systemic therapy with radiation for treatment of CNS metastasis in breast cancer patients.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
11/19/2025
Course expires: 
11/18/2027
Cost:
$149.00
Rating: 
0
  • Naamit Kurshan Gerber, MD, is employed by New York University Grossman School of Medicine. Dr. Gerber receives honoraria from the John Theurer Cancer Center and grant/research funding from PreludeDx. Dr. Gerber serves on the ASTRO APBI Guidelines committee.  
  • Mylin Torres, MD, FASTRO, is employed by Glenn Family Breast Center, Winship Cancer Institute, Emory University. Dr. Torres receives honoraria from Pfizer, Varian Medical Systems and BioAscend.
  • Icro Meattini, MD, is employed by the University of Florence. Dr. Meattini receives honoraria for serving as a consultant with Menarini StemLine, AstraZeneca, Daiichi Sankyo, Novartis, Eli Lilly, Pfizer and Gilead.
  • Sasha Beyer, MD, PhD, is employed by The Ohio State University Wexner Medical Center. 

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until November 18, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.